Skip to main content
. 2016 Jan 12;6(1):e711. doi: 10.1038/tp.2015.191

Figure 5.

Figure 5

(a and b) Reduced expression of Bdnf, Gad1, Reln, mRNAs and proteins in frontal cortex of PRS mice is normalized by treatment with clozapine. (a) Levels of mRNA relative to β-actin for Bdnf-iv, Bdnf-vi, Bdnf-ix, Gad1, Reln and (b) immunoblot of BDNF, GAD67, reelin proteins normalized by β-actin protein levels. Dose and schedule of clozapine treatment are described in Figure 2. The data are expressed as mean±s.e.m. and analyzed by one-way ANOVA followed by Student–Newman–Keuls multiple comparisons. Bdnf-ix mRNA (F3,20=3.45, P=0.026), Bdnf-iv mRNA (F3,20=4.87, P=0.015), Bdnf-vi mRNA (F3,21=3.91, P=0.018), BDNF protein (F3,20=3.33, P=0.04). GAD1 mRNA (F3,23=4.97, P=0.01), Reln mRNA (F3,23=4.68, P<0.05), GAD67protein (F3,19=4.97, P<0.05), reelin protein (F3,23=17.02, P<0.001). *P<0.05 when vehicle-treated PRS samples are compared with PRS clozapine-treated samples or with NS vehicle or clozapine-treated sample. Student–Newman–Keuls multiple comparisons. ANOVA, analysis of variance; BDNF, brain-derived neurotrophic factor; mRNA, messenger RNA; NS, nonstressed; PRS, prenatally stressed.